Nonalcoholic Fatty Liver Disease
Fernando Bril, Kenneth J. Cusi · Endocrinology and Metabolism Clinics of North America · 2016
Cited by 149 works. doi:10.1016/j.ecl.2016.06.005
Authors
References
- Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
- Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study